We report three pediatric patients with ganciclovirresistant cytomegalovirus (CMV) retinitis who were successfully treated with foscarnet. The patients were recipients of hematopoietic stem cell transplantation (SCT) from HLA-mismatched donors. Because these patients had developed or experienced progressive CMV retinitis during ganciclovir therapy, they received foscarnet therapy at 60 mg/kg every 8 h. Their retinitis resolved promptly after initiating foscarnet therapy, suggesting foscarnet's effectiveness in treating ganciclovirresistant CMV infection. The amount of CMV mRNA was quantitatively measured using an NASBA technique, which amplified the ␤2.7 transcripts specific for CMV replication. This technique was useful for monitoring disease activity in a more rapid and sensitive manner than the PCR assay for CMV DNA. Bone Marrow Transplantation (2001) 27, 1141-1145. Keywords: cytomegalovirus; ganciclovir; foscarnet; resistance; hematopoietic stem cell transplantation; NASBA Cytomegalovirus (CMV) infections are a major cause of morbidity and mortality among immunocompromised patients, especially recipients of allogeneic hematopoietic stem cell transplantation (SCT) and patients with AIDS. The measurement of CD4 + T cell count is crucial in patients at high risk of CMV retinitis; CMV retinitis develops when CD4 + T cell counts have decreased to less than 100/l. A combination of ganciclovir and intravenous immunoglobulin is effective in treating CMV diseases. However, the development of resistance to ganciclovir has been reported.
Cytomegalovirus (CMV) infections are a major cause of morbidity and mortality among immunocompromised patients, especially recipients of allogeneic hematopoietic stem cell transplantation (SCT) and patients with AIDS. The measurement of CD4 + T cell count is crucial in patients at high risk of CMV retinitis; CMV retinitis develops when CD4 + T cell counts have decreased to less than 100/l. A combination of ganciclovir and intravenous immunoglobulin is effective in treating CMV diseases. However, the development of resistance to ganciclovir has been reported. [1] [2] [3] [4] Foscarnet (trisodium phosphonoformate, PFA), a pyrophosphate analog, 5 has been used in patients with AIDS, and allogeneic SCT recipients. Because the viral inhibitory mechanism of foscarnet is distinct from that of ganciclovir, foscarnet might be useful in patients with ganciclovir-resistant CMV infection. 2, 4, 6 It usually takes 2 weeks for retinitis to heal on intravenous ganciclovir or foscarnet.
We report the clinical and virologic results of foscarnet therapy in three recipients who underwent SCT and developed ganciclovir-resistant CMV retinitis. CMV activities were monitored with a nucleic acid sequence-based amplification (NASBA) technique, [7] [8] [9] which amplified the ␤2.7 transcripts specific for CMV replication. 10 Thus, detecting CMV mRNA indicates active viral replication, which is not proven when only viral DNA is detected.
Patients and methods

Patients
This study included three patients with acute leukemia who received an allogeneic SCT between 1997 and 1999. The ages of patients 1, 2 and 3 were 10 years, 16 years and 10 months, respectively, and CMV retinitis developed 104, 103 and 42 days after SCT, respectively. The pre-transplant CMV serological status of donors and recipients was positive.
Diagnosis of CMV retinitis
Ophthalmologic evaluation: Patients were evaluated by experienced ophthalmologists using indirect ophthalmoscopy at least every 4 weeks after SCT and whenever virologic examination proved positive. Criteria for the diagnosis of CMV retinitis were the presence of typical retinal opacifications in the absence of any other causes.
Virologic evaluation: Detection of CMV mRNA in peripheral blood was performed by the NASBA method previously described. 8 The assay consisted of the following steps: isolation of total nucleic acid from 100 l of whole blood; NASBA amplification reactions using CMV-specific primers, AML RT, RNase H, and T7 RNA polymerase; a microtiter plate-based sandwich hybridization with a capture probe and a detection probe labeled with alkaline phos-phatase; and measurement of the chemiluminescence after incubating with Lumi-Phos 480. The results were shown by semiquantitative levels (1+ to 3+). The levels 1+, 2+ and 3+ corresponded to 2-20, 20-200 and Ͼ200 kilo count per second (kcps), respectively. In addition, the detection of CMV DNA in peripheral blood was performed by a single, nested polymerase chain reaction (PCR) with ethidiumbromide staining and Southern blot analysis; positive results were shown as 1+, 2+, 3+ and 4+, corresponding to 1-10, 10-100, 100-1000 and Ͼ1000 copies, respectively, in the total nucleic acid extracted from 10 5 peripheral blood mononuclear cells.
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Treatment
The initiation of pre-emptive treatment with ganciclovir was based on the detection of CMV mRNA, which indicates replication of CMV irrespective of the CMV DNA status. Ganciclovir was administered at a dose of 5 mg/kg twice daily. Foscarnet was initiated in patients in whom ganciclovir therapy had failed and development or progression of the CMV disease was observed. Foscarnet was given at a dosage of 60 mg/kg every 8 h. Immunoglobulin at a high dose was administered weekly concurrently with ganciclovir or foscarnet therapy.
Case reports
Patient 1
The clinical course is shown in Figure 1 . A 10-year-old girl with acute lymphoblastic leukemia (ALL) underwent SCT from an HLA-mismatched (two antigens mismatched) unrelated donor in first complete remission. Since peripheral blood became positive for CMV mRNA and DNA on day 26 post SCT, she received 5 mg/kg of ganciclovir twice daily for 42 days. Despite this therapy, the CMV mRNA level remained elevated, suggesting emergence of a CMV mutant resistant to ganciclovir. Because of myelosuppres- sion (leukocyte count was 1320/l), the ganciclovir dose was reduced to 2.5 mg/kg twice daily. Following the reduction of ganciclovir therapy, CMV retinitis developed on day 104 when the CD4 + T cell count was 102/l, and the ganciclovir dose was increased at 5 mg/kg twice daily. Since the retinitis progressed, foscarnet therapy (60 mg/kg every 8 h) was initiated on day 111. Two weeks later, the retinitis improved with a good virologic response. During subsequent foscarnet therapy of 180 mg/kg and 90 mg/kg every other day, the CMV mRNA level became elevated again on day 180, and the retinitis again progressed on day 202, at which time the CD4 + T cell count was 147/l. Foscarnet was increased to 60 mg/kg every 8 h for 1 week, and the retinitis became stable again on day 209. However, the CMV mRNA remained elevated, suggesting emergence of a foscarnet-resistant CMV mutant. Thereafter, she received foscarnet therapy at 180 mg/kg and 90 mg/kg every other day, and then 90 mg/kg of foscarnet was administered three to five times per week until day 326. As the CD4 + T cell counts increased to more than 300/l, the CMV mRNA level declined.
Patient 2
The clinical course is shown in Figure 2 . A 16-year-old female with ALL underwent allogeneic SCT from an HLAmismatched (two antigens mismatched) sibling in second complete remission. She received pre-emptive ganciclovir therapy (5 mg/kg twice daily for 25 days, then 2.5 mg/kg twice daily) from day 27 post SCT because the CMV mRNA level was elevated. However, CMV retinitis subsequently developed with a renewed elevation of CMV mRNA on day 103, at which time the CD4 + T cell count was 101/l. Although ganciclovir was instituted again at 5 mg/kg twice daily, progression of retinitis was observed on day 112. Foscarnet therapy was therefore initiated at 60 mg/kg every 8 h. Improvement was noted on day 119, although the possibility of a delayed response to ganciclovir could not be excluded. Foscarnet therapy was discontinued on day 206. However, a new retinitis lesion with elevation of the CMV mRNA level without viral DNA was observed on day 320, at which time the CD4 + T cell count was between 148/l (day 252) and 213/l (day 348), and foscarnet therapy was reinstituted at 60 mg/kg three times weekly. One week later, her fundus showed inactive retinal scarring. Thereafter, a reduced foscarnet dose of 60-80 mg/kg twice weekly was administered without retinitis progression. During therapy, an occasional increase of the CMV mRNA level was observed without detecting viral DNA.
Patient 3
The clinical course is shown in Figure 3 . A 10-month-old girl with acute myeloblastic leukemia (M5) underwent SCT with positively selected CD34 + cells from the peripheral blood of her HLA-mismatched (two antigens mismatched) mother after graft failure of an unrelated cord blood transplant. After the cord blood transplant, she received preemptive ganciclovir therapy for CMV mRNA elevation. 
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Eighteen days after the second transplant, her blood became positive for CMV mRNA, at which time the CD4 + T cell count was 32/l, and ganciclovir therapy was then reinstituted at 5 mg/kg twice daily. However, the CMV mRNA level continued to be elevated. Subsequently, foscarnet was initiated at 60 mg/kg every 8 h on day 41. One day later, ophthalmologic examination revealed CMV retinitis. Foscarnet therapy of 180 mg/kg/day for 17 days, followed by 90 mg/kg/day for 7 days, resulted in an improvement of the retinitis and CMV mRNA disappeared. Thereafter, CMV mRNA remained negative, perhaps owing to recovery of the CD4 + T cell counts.
Discussion
Despite ganciclovir therapy of 5 mg/kg twice daily, the retinitis developed or progressed in these three patients. It usually takes 2 weeks for retinitis to heal after initiating intravenous ganciclovir or foscarnet. Patients 1 and 3 developed retinitis despite receiving ganciclovir therapy for more than 3 weeks. The retinitis of patient 2 progressed after 9 days of ganciclovir therapy. Since subretinal fluid ganciclovir levels are similar to those in serum following intravenous administration, failures of drug delivery and penetration were unlikely, and emergence of ganciclovirresistant strains was suggested. During the subsequent foscarnet therapy, clinical improvement was observed and the CMV mRNA level was reduced in all patients, although the possibility that the retinitis of patient 2 exhibited a delayed response to ganciclovir could not be excluded.
Ganciclovir is clinically effective in most patients with CMV disease. However, refractory CMV disease has been reported in association with isolation of ganciclovir-resistant CMV strains. [1] [2] [3] [4] Mutations in CMV UL97 phosphotransferase have been observed in ෂ90% of ganciclovirresistant clinical CMV isolates. 12, 13 Since foscarnet is a pyrophosphate analog that does not require phosphorylation for its activity, 5 resistance to foscarnet is not expected to result from mutations in UL97. In some clinical isolates, Pol mutations also contribute to ganciclovir resistance.
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Although we did not examine viral susceptibility to ganciclovir or mutations of CMV isolates, it is likely that ganciclovir-resistant CMV strains caused the retinitis in these patients.
Foscarnet is virostatic and viral replication restarts as soon as the drug is cleared from infected cells. Therefore, maintenance therapy should be continued until the infection can be controlled by the immune system. The CMV mRNA occasionally became positive during maintenance treatment in patients 1 and 2, and the retinitis progressed again during foscarnet therapy at a lower dose in patient 1. However, the readministration of foscarnet at the induction dose of 180 mg/kg/day yielded a good response. In this study, recurrences were documented at lower than 200/l of CD4 + T cells in peripheral blood, suggesting that maintenance therapy with foscarnet should be continued until the number of CD4 + T cells reaches 200/l to prevent recurrence. Combined therapy with ganciclovir and foscarnet has been reported to be effective in preventing resistance with no increased frequency of systemic toxic reactions. [14] [15] [16] [17] In the future, initial pre-emptive therapy with this combination might be considered in patients with prolonged immunosuppression.
In recent years, various methods have been used for the rapid and early determination of viremia and antigenemia to reduce the mortality and morbidity related to CMV infections. 18, 19 In this study, we monitored and analyzed CMV activities using an NASBA technique, which is highly suited for the amplification of RNA sequences. [7] [8] [9] We amplified the ␤2.7 transcripts of the CMV, which is detected concomitantly with active viral replication. 10 Thus, viral activation is indicated by detecting mRNA not viral DNA. In all three patients, the CMV mRNA level was elevated before the onset of CMV retinitis and became negative in parallel with clinical resolution. In patient 2, while CMV DNA was not detected, CMV mRNA became positive, and on one occasion, retinitis developed. Therefore, mRNA was detected by NASBA earlier and was more sensitive than the detection of DNA, suggesting that monitoring CMV mRNA is useful for treating a CMV infection in the clinical setting.
